Focus Partners Wealth Has $197.57 Million Stock Holdings in Abbott Laboratories $ABT

14 Jun 2026, 12:13 by Tristan Rich · The Markets Daily

Focus Partners Wealth lifted its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 197.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,576,873 shares of the healthcare product maker’s stock after purchasing an additional 1,045,870 shares during the quarter. Focus Partners Wealth’s holdings in Abbott Laboratories were worth $197,567,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $25,000. Harbor Capital Advisors Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $27,000. Intesa Sanpaolo Wealth Management bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $29,000. Finally, Prudent Man Investment Management Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $33,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $87.89 on Friday. The stock has a market capitalization of $153.08 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.47 and a beta of 0.63. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $91.46 and a two-hundred day moving average price of $107.98.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ABT shares. BofA cut their price target on Abbott Laboratories from $120.00 to $102.00 in a report on Friday. Piper Sandler cut their price target on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Wells Fargo & Company cut their price target on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Royal Bank Of Canada cut their price target on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Finally, Barclays dropped their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.38.

Read Our Latest Report on Abbott Laboratories

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Insider Activity

In related news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction dated Monday, April 27th. The stock was bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.